Document is current

Article History

Accepted: 16 March 2023

First Online: 4 May 2023

Competing interests

: K.R.C. declares that he has received honoraria for advisory board membership from 4D Pharma, AbbVie, Acadia, Britannia, Global kinetics (GKC), Lobsor, Profile Pharma, Roche, Scion, Stada, Synovion, Therevance, UCB and Zambon; speaker’s honoraria for lectures from AbbVie, Bial, Boeringer Ingelheim, Britannia, Kyowa Kirin, Novartis, SK Pharma, UCB, and Zambon; investigator initiated research grants from AbbVie, Bial; Britannia, UCB, Global Kinetics; and academic grant funding from EU Horizon 2020, Parkinson’s UK, Wellcome Trust, Kirby Laing Foundation and the Medical Research Council; royalty payments or license fees from Oxford University Press, and Cambridge University Press, MAPI institute (King’s Parkinson Disease Pain Scale (KPPS) and Parkinson Disease Sleep Scale 2 (PDSS-2)); and payment for expert testimony from the General Medical Council unrelated to the submitted work. V.L. declares that she has received grants and/or honoraria for speaker-related activities from Abbvie, Bial, Britannia Pharmaceuticals, Invisio, Profile and UCB unrelated to the submitted work. P.S. declares that he has received honoraria for advisory board membership from AbbVie, Kyowa Kirin and Takeda; honoraria for lectures from AbbVie and Zambon; and academic grants from, Lexa International/Nordstjernan, Michael J. Fox Foundation, Stockholm City Council and Wallenberg Clinical Scholarship unrelated to the submitted work. The other authors declare no competing interests.